Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 6/20 | 0.48 |
| ▸ | IGF1R | P08069 | 14/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937533 | 0.91 | TNK2 (0.47) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL400538 | 0.91 | TNK2 (0.47) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL10189260 | 0.87 | TNK2 (0.61) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL2967554 | 0.87 | TNK2 (0.61) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL398156 | 0.87 | TNK2 (0.61) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL27678730 | 0.82 | TNK2 (0.46) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL2574212 | 0.82 | TNK2 (0.43) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL19264285 | 0.80 | TNK2 (0.48) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL402204 | 0.78 | TNK2 (0.37) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL6938221 | 0.78 | TNK2 (0.37) | TNK2IGF1RCYP3A4MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314111-B2 | Fused bicyclic motor inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | OSI Pharmaceuticals, LLC | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | MTOR, RICTOR, MAPKAP1 | TNK2 669/4885IGF1R 1033/4885CYP3A4 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.